Blue Cross commercial and BCN commercial Categories: Authorizations/referrals, Pharmacy

Date posted: Dec. 9, 2025

Stoboclo, Osenvelt and denosumab-bmwo (unbranded) to have a site-of-care requirement for most commercial members starting March 9

For dates of service on or after March 9, 2026, we're adding a site-of-care requirement for most Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members for the following drugs covered under the medical benefit:

- Stoboclo[®] (denosumab-bmwo), HCPCS code Q5157
- Osenvelt® (denosumab-bmwo), HCPCS code Q5157
- denosumab-bmwo (unbranded), HCPCS code Q5157

When requesting prior authorization, you'll be prompted to select a site of care when you submit prior authorization requests for these drugs. If the request meets the clinical criteria for the drug and is for one of the following sites of care, it will be automatically approved:

- Doctor's or other health care provider's office
- Ambulatory infusion center
- The member's home, from a home infusion therapy provider

Additional information or documentation may be required for requests to administer Stoboclo, Osenvelt and denosumab-bmwo (unbranded) in an outpatient hospital setting.

As a reminder, these drugs already require prior authorization. The new site-of-care requirement is in addition to the current prior authorization requirement.

Members who start courses of treatment with Stoboclo, Osenvelt and denosumab-bmwo (unbranded) before March 9, 2026, will be able to continue receiving this drug in their current location until their existing authorization expires. If these members then continue treatment under a new prior authorization, the site-of-care requirement outlined above will apply.

Some Blue Cross commercial groups aren't subject to these requirements

For Blue Cross commercial, prior authorization and site-of-care requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list.

While UAW Retiree Medical Benefits Trust non-Medicare members don't participate in the standard prior authorization program, these requirements apply to them.

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Blue Cross commercial and BCN commercial Categories: Authorizations/referrals, Pharmacy

Date posted: Dec. 9, 2025

Note: These requirements don't apply to Blue Cross and Blue Shield Federal Employee Program[®] members.

Lists of requirements

For more information about requirements related to drugs covered under the medical benefit, see these lists:

- Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members
- Medical Drug Management with Blue Cross for UAW Retiree Medical Benefit Trust PPO non-Medicare members

We'll update these lists prior to the effective date.

You can access these lists and other information about requesting prior authorization on the <u>Medical Benefit Drugs</u> pages on **authorizations.bcbsm.com**.

Prior authorization isn't a guarantee of payment. Health care providers need to verify eligibility and benefits for members.

<u>Subscribe</u> to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.